

4DMEDICAL TO PRESENT AT NWR VIRTUAL INVESTOR CONFERENCE

28 July 2021: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a medical technology company focused on commercialising its FDA cleared and TGA approved respiratory imaging platform, is pleased to announce that Managing Director and CEO, Dr Andreas Fouras, will be presenting at the NWR Virtual Investor Conference at 10:50am AEST on Tuesday 3rd August 2021.

Event: NWR Communications Virtual Investor Conference
Presenting: Andreas Fouras, Managing Director & CEO
Time: 10:50am AEST, Tuesday 3rd August 2021

Investors can register for the session at the following link:

https://us02web.zoom.us/webinar/register/WN_rBD8G0BFS8y0fMUMTzvLBg

After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the webinar at the same link.

Investors are invited to submit questions prior to the webinar to: shinsley@4dmedical.com.

ENDS

Authorised by Andreas Fouras, Managing Director and CEO.

Contacts:

<i>Corporate</i>	<i>Investor</i>	<i>Media</i>
Charlene Stahr	Simon Hinsley	Matthew Wright
Company Secretary	+ 61 401 809 653	+ 61 451 896 420
companysecretary@4dmedical.com	shinsley@4dmedical.com	matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.